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Background. We used a random sample (n = 2,495) from the population-based Prevention of Renal and Vascular End-stage
Disease (PREVEND) study population to examine the association of the metabolic syndrome (Met S) with plasminogen activator
inhibitor type 1 (PAI-1) and tissue plasminogen activator (t-PA) antigen levels. Results. The overall prevalence of the Met S was
18%, was dependent on age and gender, and was positively associated with higher antigen levels of both PAI-1 and t-PA. These
signiﬁcant eﬀects were maintained after adjustment for age, gender, BMI, elevated C-reactive protein, smoking status, urinary
albumin excretion, and insulin levels. We found no signiﬁcant interactions between the Met S and other covariates on PAI-1 and t-
PA levels. Conclusions. Our study demonstrates that those with the Met S have signiﬁcantly higher levels of PAI-1 and t-PA antigen,
factors known to increase the risk of cardiovascular disease.
1.Introduction
The metabolic syndrome (Met S)—characterized by insulin
resistance, abdominal obesity, hypertriglyceridemia, low
high-density lipoprotein (HDL) cholesterol, hypertension,
and hyperglycemia—is becoming increasingly common. The
Met S has been demonstrated to be a risk factor for
cardiovascular disease [1] and type 2 diabetes [2]. Reported
diﬀerences in the prevalence of the Met S among various
ethnic groups [3] highlight the need to use population-
based studies to examine descriptive epidemiology of the
syndrome. Further, limited information is available on its
associationwithplasminogenactivatorinhibitortype1(PAI-
1) and tissue-type plasminogen activator (t-PA) antigen
levels,bothofwhicharebiomarkersofﬁbrinolysisassociated
with an increased risk of cardiovascular disease [4–6].
We were also interested in how two more recently identi-
ﬁed risk factors for cardiovascular disease—high-sensitivity
(hs) C-reactive protein and microalbuminuria—might aﬀect
associations observed between the Met S and PAI-1 and t-
PA antigen levels. High sensitivity C-reactive protein is a
sensitive indicator of low-grade inﬂammation. C-reactive
protein has been demonstrated to be an independent risk
factor for cardiovascular disease [7, 8] ,a n di ti sp o s i t i v e l y
associated with both the Met S [9] and PAI-1 antigen
levels [10]. Microalbuminuria, generally deﬁned as a urinary
albumin excretion of 30–300mg per 24 hours [11], has
been demonstrated to be an independent risk factor for2 Cardiology Research and Practice
cardiovascular disease and mortality [12, 13]. Its appearance
in the urine, in addition to renal pathology, indicates early
vascular and endothelial damage in the vascular tree in
general [14], and it is positively associated with both the Met
S[ 15]a n dP A I - 1l e v e l s[ 16, 17].
W h i l ep r e v i o u ss t u d i e sh a v eg e n e r a l l yr e p o r t e dp o s i t i v e
associations between the Met S and PAI-1 and t-PA antigen
levels [3, 18], few, if any, large population-based studies
have controlled for C-reactive protein levels or albuminuria
status or considered possible interactions between the Met
S and other key variables on PAI-1 and t-PA antigen
levels. The availability of a large population-based sample of
subjects with detailed clinical data provided an opportunity
to describe the Met S in a Dutch population and to examine
the association of the Met S with PAI-1 and t-PA antigen
levels, taking into account potential confounders and/or
eﬀect modiﬁers.
2.MaterialsandMethods
2.1. PREVEND Sample. This study is part of the ongoing
Prevention of Renal and Vascular ENd-stage Disease (PRE-
VEND) study, a large prospective study among inhabitants
of the city of Groningen, the Netherlands. Details of the
study protocol have been described elsewhere [12]. In brief,
all inhabitants of the city between the ages of 28 and
75 (85,421 subjects) were asked to send in a morning
urine sample and to ﬁll out a short questionnaire on
demographics and cardiovascular history. A total of 40,856
(47.8%) responded. From this group, 30,890 subjects had a
urinary albumin concentration <10mg/L and 9,996 subjects
had a urinary albumin concentration of ≥10mg/L in their
morning urine sample. After exclusion of subjects with type
1 diabetes mellitus and women who were possibly pregnant,
all subjects with a urinary albumin concentration ≥10mg/L
(n = 7,768) and a randomly selected control group with
a urinary albumin concentration <10mg/L (n = 3,395)
were invited for further investigations in an outpatient
clinic (total n = 11,163). The screening program in the
outpatient clinic consisted of two visits. At the ﬁrst visit,
participants completed a self-administered questionnaire
regarding demographics, cardiovascular and renal history,
and drug use. At the second visit, blood was drawn after
an overnight fast for determination of plasma glucose and
serum creatinine. Finally, 8592 subjects completed the total
screening program and form the baseline PREVEND cohort.
From this cohort, we selected a random sample of 2,527
subjects representative of the entire PREVEND cohort.
Of these, 32 subjects were missing a suﬃcient number
of components of the Met S such that it could not be
determined whether or not they had the Met S. Hence,
this analysis is based on the subset of 2,495 subjects in the
random sample with complete information regarding the
Met S. The PREVEND study was approved by the local
medical ethics committee and conducted in accordance with
the guidelines of the declaration of Helsinki. All participants
who attended the outpatient clinic gave written informed
consent.
2.2. Measurements. Stored plasma samples collected at base-
line were thawed and assayed by the Haemoprobe laboratory
(Groningen, The Netherlands) using ELISA kits from Tech-
noclone GmbH (Vienna, Austria). These assays measured
both free and bound PAI-1 and t-PA antigen levels and have
been described in detail elsewhere [19].
The metabolic syndrome was the primary independent
variable of interest. For the purposes of the described
analyses, the Met S was deﬁned using the modiﬁed criteria
of the National Cholesterol Education Program, Third
Adult Treatment Panel [20]. Individuals with 3 or more
of the following components were categorized as having
the overall syndrome: (1) abdominal obesity (waist mea-
surement >102cm for men and >88cm for women); (2)
hypertriglyceridemia (>1.69mmol/L (150mg/dL)); (3) low
HDL cholesterol (≤1.03mmol/L (40mg/dL) in men and
≤1.29mmol/L (50mg/dL) in women); (4) high blood pres-
sure(≥130mmHgsystolicand/or ≥85mmHgdiastolicBP);
(5) high fasting glucose (>5.5mmol/L (100mg/dL)). Waist
and hip measurements were performed by several research
nurses and medical students at the outpatient clinic for the
PREVENDstudy.Waistcircumferencewasmeasuredonbare
skin at the natural indentation between the 10th rib and iliac
crest. Systolic and diastolic BPs were calculated as the average
of the last two measurements taken at two clinic visits. After
removal of shoes and heavy clothing, weight was measured
to the nearest 0.5kg using a Seca balance scale (Seca Vogel
& Halke GmbH & Co, Hamburg, Germany). Height was
measured to the nearest 0.5cm. Blood samples were drawn
after an overnight fast. Glucose was determined by Kodak
Ektachem dry chemistry (Eastman Kodak, Rochester, NY,
USA), an automatic enzymatic method. Triglycerides were
measured enzymatically. A commercially available assay
system was used to assess HDL cholesterol (Abbott Inc.,
Abbott Park, IL, USA). High-sensitivity C-reactive protein
was determined by nephelometry with a threshold of
0.175mg/L and intra- and interassay coeﬃcients of less than
4.4%and5.7%,respectively(BNIN,DadeBehring,Marburg,
Germany).
Age was subdivided into categories of <40, 40–60,
and >60 years of age. Smoking was deﬁned as a current
smoker or cessation of smoking less than a year before the
study. BMI was subdivided into categories of <25, 25–30
(overweight), and >30 (obese) kg/m2. Elevated C-reactive
protein was deﬁned as a level >3mg/L. Urinary albumin
excretion (UAE) was measured as the mean of two 24-
hour urine collections. Participants were categorized as hav-
ing normoalbuminuria (<30mg/24h), microalbuminuria
(30–300mg/24h), or macroalbuminuria (>300mg/24hr).
Insulin levels were subdivided into categories of <8, 8–12,
and >12µU/mL. Diabetes was deﬁned as a fasting plasma
glucose level >7.0mmol/L, a nonfasting plasma glucose level
>11.1mmol/L, or the use of glucose-lowering medication.
2.3. StatisticalAnalyses. We initially described the prevalence
of the Met S by gender and age. Logarithmic transformations
were used to normalize the distributions of PAI-1 and t-PA
levels. Although reported P values are for comparisons of the
log-transformed means, we report medians and interquartileCardiology Research and Practice 3
Table 1: Characteristics of the study population by presence or absence of the metabolic syndrome.
Metabolic syndrome P value
Present (N = 440) Absent (N = 2055)
Age at baseline <.00011
<40yrs (%) 8.9 91.1
40–60yrs (%) 17.5 82.5
>60yrs (%) 26.9 70.1
Gender <.00011
Male (%) 20.9 79.1
Female (%) 14.8 85.2
BMI <.00011
<25kg/m2 (%) 3.7 96.4
25–30kg/m2 (%) 22.7 77.3
>30kg/m2 (%) 53.1 47.0
Smoker .5061
Yes (%) 18.4 81.6
No (%) 17.3 82.7
C-reactive protein <.00011
≥3.0mg/L (%) 33.0 67.0
<3.0mg/L (%) 13.4 86.6
Urinary albumin excretion <.00011
<30mg/24h (%) 15.7 84.3
30–300mg/24h (%) 44.9 55.2
>300mg/24h (%) 80.0 20.0
Insulin levels <.00011
<8µU/mL (%) 5.1 94.9
8–12µU/mL (%) 18.6 81.4
>12µU/mL (%) 45.3 54.7
PAI-1 antigen (ng/mL) (median (IQR)) 126.7 (81.4, 194.2) 57.3 (35.5, 99.7) <.00012
t-PA antigen (ng/mL) (median (IQR)) 3.9 (2.8, 6.0) 2.9 (2.2, 4.2) <.00012
BMI: body mass index; PAI-1: plasminogen activator inhibitor type 1; t-PA: tissue-type plasminogen activator; IQR: interquartile range.
1Chi-square test, 2T-test based on log values.
ranges (IQR) for summary statistics since such comparisons
are more similar to a comparison of medians than means in
the original metric. Univariate linear models were used to
examine the individual eﬀects of the Met S, age at baseline,
gender, BMI, smoking status, elevated C-reactive protein,
albuminuria status, and insulin levels with PAI-1 and t-PA
levels. We also used multivariable linear regression models
with backwards selection and split-sample validation to
explore whether the association of the Met S with PAI-1 and
t-PAlevelsheldupafteradjustingfortheothervariables.The
fullmodelofinterestincludedallfactorsaswellasallpossible
two-way interactions between each factor and the Met S.
At each step, the interaction term with the highest P value
(provided it was >.10) was removed from the model and the
model was reﬁt with all remaining terms. This process was
continued until either no interaction terms remained or all
remaining interactions were signiﬁcant.
Since it is well known that models obtained using such
data-driven methods are prone to increased type 1 errors
[21], proper validation of such models is crucial. For this
analysis, model validation was performed using the split-
sample validation techniques as described in Muller and
Fetterman [22].Essentially,thisinvolvessplittingtheanalysis
dataset into a training and hold-out sample. The shrinkage
statistic is deﬁned as the diﬀerence between the R2 value
in the ﬁnal model obtained using the training sample and
the cross-validity coeﬃcient calculated from the holdout
sample. Small values of relative shrinkage imply better
generalizabilityoftheﬁnalmodel.Allstatisticalanalyseswere
performed using SAS version 9.1.
3. Results and Discussion
3.1. Description of Met S in the Population. The average age
of the study population was 48 years and 53% were women.
The overall prevalence of the Met S in the population was
18% and rose with age in both genders. Although the overall
prevalence was signiﬁcantly higher in men than in women
(21% versus 15%, P<. 01), the prevalence was dependent on
age and gender. As shown in Figure 1, in subjects less than 40
years, the prevalence was signiﬁcantly higher in men (13%
versus 6%, P<. 01). In contrast, there was no signiﬁcant4 Cardiology Research and Practice
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Figure 1: Prevalence of the metabolic syndrome by gender and age.
diﬀerence in the prevalence for men and women over 60
years (31% versus 29%, P = .46).
Table 1 shows the characteristics of the study population
by the presence or absence of the Met S. The Met S was
positively associated with all covariates except smoking. We
also examined the frequency of type 2 diabetes by the
presence or absence of the Met S. The presence of diabetes
was highly correlated with the Met S (75% of diabetics had
the Met S versus 16% of nondiabetics, P<. 001).
3.2. Association of Met S and Other Covariates with PAI-
1A n t i g e nL e v e l s .The results from the univariate models
indicate that an older age at baseline, male gender, higher
BMI, smoking, elevated hs C-reactive protein, elevated UAE,
and elevated insulin levels were positively associated with
PAI-1 antigen levels (Table 2). In addition, PAI-1 levels
were signiﬁcantly higher among those with the Met S as
opposed to those without the Met S (median (IQR): 126 (81,
194)ng/ml versus 59 (36, 103ng/ml), P<. 001).
From the backwards selection algorithm using the train-
ing sample, there were no signiﬁcant interactions. Cross-
validation produced a negative shrinkage statistic which
implies a reasonable ﬁt. The results from the ﬁnal multivari-
able model applied to the combined datasets are shown in
Table 2. The previously observed associations between PAI-1
levels and both UAE and hsCRP went away after adjustment
for the other variables. All other variables, including the Met
S, continued to have a signiﬁcant relationship with PAI-1
levels after adjustment.
3.3. Association of Met S and Other Covariates with t-PA Anti-
gen Levels. The results from the univariate models (Table 3)
indicate that increasing age at baseline, male gender, higher
BMI, not smoking, elevated C-reactive protein, and elevated
insulin levels were positively associated with t-PA levels.
Further, median t-PA levels were signiﬁcantly higher among
those with the Met S as opposed to those without the
Met S (median (IQR): 3.9 (2.8, 6.0) ng/ml versus 2.9 (2.2,
4.2)ng/ml, P<. 001).
From the backwards selection algorithm using the train-
ing sample, as before, there were no signiﬁcant interac-
tions. Furthermore, cross-validation produced a near zero
shrinkage statistic which implies a reasonable ﬁt. The results
from the ﬁnal multivariable model applied to the combined
datasets are shown in Table 3. The previously observed
relationships between t-PA levels and BMI, smoking status,
and C-reactive protein disappear after adjustment. After
adjustment for all other covariates, the Met S, increasing
age at baseline, male gender, and elevated insulin levels
continued to have a signiﬁcant eﬀect on t-PA levels.
3.4. Prevalence of Met S. The overall prevalence rate of 18%
in our Dutch population and the greater prevalence in men
as compared to women are similar to ﬁndings reported for
other adult European populations. Hu et al. [23]r e p o r t e d
an overall prevalence of the Met S of 15% in nondiabetic
adult Europeans based on 11 study cohorts. If those with
type 2 diabetes are removed from our Dutch population, the
prevalence of the Met S is reduced to 16%, similar to that
found in the study by Hu and others.
3.5. Association of Met S with PAI-1 and t-PA Antigen Levels.
There remained a signiﬁcant positive association between
the Met S and both PAI-1 and t-PA antigen levels after
adjustment for the covariates of interest. These associations
also remained when participants with type 2 diabetes were
excluded from the models (results not shown). Further,
after adjustment all other covariates with the exception of
UAE continued to have a signiﬁcant eﬀect on PAI-1 levels,
whereas, in addition to the Met S, only age, gender, and
insulin levels had signiﬁcant eﬀects on t-PA levels.
Our ﬁndings of an association between the Met S
and PAI-1 and t-PA antigen levels are generally consistent
with the ﬁndings of previously conducted studies [3, 18].
Anand et al. [3] also demonstrated a reduction in clot
lysis time after induced ischemia by venous cuﬀ occlusion,
further supporting impaired ﬁbrinolytic function in those
with the Met S. Our study extends previous ﬁndings of
an association between the Met S and PAI-1 and t-PA
antigen levels by adjusting for a number of covariates and by
exploring potential interactions between the Met S and these
covariates.
The link between PAI-1 and Met S is complex, and
several mechanisms could contribute to the elevated PAI-1
concentrations in Met S patients [24]. One of the proposed
mechanisms is the contribution of the rennin-angiotensin
system on PAI-1 synthesis. Angiotensin-converting enzyme
inhibition has been shown to reduce PAI-1 levels in obese
patients [25], and angiotensin II promotes PAI-1 excretion
in human adipocytes [26]. In addition, the expression
of rennin-angiotensin system genes is regulated diﬀerently
in obese subjects [27], and a combination of variants
in rennin-angiotensin system genes was associated with
the Met S. Interestingly, our group previously found that
polymorphisms in genes from the rennin, angiotensin, andCardiology Research and Practice 5
Table 2: PAI-1 antigen levels (ng/mL) for the association of the metabolic syndrome and other covariates.
Median (IQR) Univariate models Multivariable model
Age at baseline <0.001 <0.001
<40yrs 51 (32, 89)
40–60yrs 72 (42, 123)
>60yrs 80 (47, 138)
Gender <0.001 <0.001
Male 75 (46, 132)
Female 59 (34, 107)
BMI <0.001 <0.001
<25kg/m2 (%) 49 (31, 79)
25–30kg/m2 (%) 80 (49, 143)
>30kg/m2 (%) 115 (71, 189)
Smoking status <0.001 <0.001
Current/former 70 (43, 126)
Nonsmokers 64 (37, 114)
C-reactive protein <0.001 0.633
≥3.0mg/L 84 (45, 152)
<3.0mg/L 63 (38, 109)
Urinary albumin excretion <0.001 0.303
<30mg/24h (%) 66 (39, 116)
30–300mg/24h (%) 80 (48, 154)
>300mg/24h (%) 104 (68, 134)
Insulin levels <0.001 <0.001
<8µU/mL (%) 52 (34, 82)
8–12µU/mL (%) 77 (44, 128)
>12µU/mL (%) 114 (71, 181)
Metabolic syndrome <0.001 <0.001
Present 126 (81, 194)
Absent 59 (36, 103)
PAI-1 levels were missing in 29 (1.2%) of subjects.
bradykinin system were related to PAI-1 and t-PA levels and
this relationship was dependent on body size as assessed by
body mass index and waist-to-hip ratio [28, 29]. Further
research is needed to further elucidate the underlying
mechanisms responsible for the observed relation between
PAI-1, t-PA, and the Met S.
The positive associations of PAI-1 with age, male gender,
BMI, smoking, and insulin levels as well as the positive
associations of t-PA with age, male gender, and insulin
levels have been reported elsewhere [10, 30–35]. The lack of
association between C-reactive protein with PAI-1 and t-PA
levelsisinterestingandmaysuggestthattheelevationofPAI-
1 may be due to production of PAI-1 by adipose tissue and
lessasaresponsetochangesininﬂammatorystatus.Thislack
of association has been reported previously [36]. The lack
of association of UAE with PAI-1 levels and of smoking and
obesity with t-PA levels was unanticipated since associations
have been previously reported [16, 17, 31, 37].
3.6. Strengths and Limitations. Strengths of our research
include the fact that the sample used for analysis was
population-based and therefore more representative of the
general adult population than would be other population
groups. Further, our sample size was relatively large and
we had data available on a large number of variables
including hs C-reactive protein and UAE, novel risk factors
for cardiovascular disease associated with both the Met S and
PAI-1 antigen levels.
There were also several limitations of our study. As our
study was cross-sectional, although the associations between
the Met S and PAI-1 and t-PA antigen levels remained
after control for other covariates, we are unable to evaluate
causality. One possibility, consistent with the hypothesis that
the increase in cardiovascular disease among individuals
with the Met S occurs at least in part through thrombotic
mechanisms, is that the Met S causes elevations of PAI-1
and t-PA levels. Alternatively, it has been hypothesized that
PAI-1 levels may play a causal role in the development of
obesity and the Met S [24]. This is a promising hypothesis as
PAI-1 was recently demonstrated to predict the development
of type 2 diabetes in the prospective Insulinpagebreak
Resistance Atherosclerosis Study (IRAS) [38]. Hence, the
choice of PAI-1 and t-PA antigen levels as the endpoints
for the study was somewhat arbitrary since, although the6 Cardiology Research and Practice
Table 3: t-PA antigen levels (ng/mL) for the association of the metabolic syndrome and other covariates.
Median (IQR) Univariate models Multivariable model
Age at baseline <0.001 <0.001
<40yrs 2.7 (1.9, 3.5)
40–60yrs 3.1 (2.3, 4.4)
>60yrs 3.7 (2.7, 5.7)
Gender <0.001 <0.001
Male 3.3 (2.4, 4.9)
Female 2.8 (2.1, 4.0)
BMI <0.001 0.153
<25kg/m2 (%) 2.7 (2.1, 3.7)
25–30kg/m2 (%) 3.4 (2.4, 5.1)
>30kg/m2 (%) 3.6 (2.6, 4.9)
Smoking status 0.042 0.391
Current/former 3.0 (2.2, 4.4)
Nonsmokers 3.1 (2.3, 4.5)
C-reactive protein 0.001 0.418
≥3.0mg/L 3.3 (2.3, 4.9)
<3.0mg/L 3.0 (2.2, 4.3)
Urinary albumin excretion 0.10 0.383
<30mg/24h (%) 3.0 (2.2, 4.4)
30–300mg/24h (%) 3.3 (2.4, 5.0)
>300mg/24h (%) 4.6 (4.2, 6.3)
Insulin levels <0.001 <0.001
<8µU/mL (%) 2.8 (2.1, 3.8)
8–12µU/mL (%) 3.2 (2.3, 4.7)
>12µU/mL (%) 3.6 (2.6, 5.7)
Metabolic syndrome <0.001 0.002
Present 3.9 (2.8, 6.0)
Absent 2.9 (2.2, 4.2)
t-PA levels were missing in 26 (1.0%) of subjects.
Met S may inﬂuence PAI-1 and t-PA levels, PAI-1 has also
been hypothesized to causally inﬂuence obesity and the Met
S. It would also be of interest to know whether the subjects
were on statin therapy, receiving other lipid lowering drugs,
or receiving ACE inhibitors or ARBs. Unfortunately, the
PREVEND database does not include detailed information
regarding the use of statins or ARBs. Only a small percentage
of subjects were found to be receiving any ACE inhibitor
(4.4%) or any lipid lowering medication (5.0%), which
suggeststhatthiswouldhaveaminimalimpactontheoverall
conclusions of the study. Finally, due to the size of the
study and the curse of dimensionality, we did not explore
interactions among the covariates of interest nor did we
explore interactions higher than second order among the
covariates and the Met S. Hence, we may have missed an
important higher-order interaction among the variables of
interest.
4. Conclusions
In conclusion, the present study demonstrates that those
with the Met S have higher levels of PAI-1 and t-PA
antigen, factors known to increase the risk of cardiovascular
disease. However, prospective studies are needed to establish
causality. To demonstrate that the Met S causes increases in
PAI-1 and t-PA antigen levels that result in cardiovascular
disease requires monitoring changes in these ﬁbrinolytic
variables, in addition to the development of clinical events,Cardiology Research and Practice 7
in subjects with and without the Met S. Alternatively, to
determine if PAI-1 is an underlying cause of the Met S would
require examining the associations of baseline levels of PAI-1
withincidentcasesoftheMetS.Aftercausalityisestablished,
clinicaltrials willbe needed toinvestigate whetherlifestyleor
pharmacologicinterventionstargetedtoimproveﬁbrinolytic
function reduce cardiovascular events in subjects with the
Met S or, alternatively, are eﬀective in preventing the Met S.
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